Trial of preventing hypertension: Design and 2-year progress report

Hypertension

Volumn 44, Issue 2, 2004, Pages 146-151

  Julius, Stevo ^a   Nesbitt, Shawna ^c   Egan, Brent ^d   Kaciroti, Niko ^a   Schork, M Anthony ^b   Grozinski, Melissa ^e   Michelson, Eric ^e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Angiotensin antagonist; Blood pressure; Hypertension, detection and control; Receptors, angiotensin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELIMINATION; FEMALE; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES;

EID: 3543038818     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000130174.70055.ca     Document Type: Article

References (23)

1. Julius S, Schork MA. Borderline hypertension-a critical review. J Chronic Dis. 1971;23:723-754.
2. U.S. Department of Health and Human Services, National Institutes of Health. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication No. 03-5233. May 2003.
3. Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. 2nd ed, vol 1. New York, NY: Raven Press; 1995:127-144.
4. Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertensive safer withdrawal of long term antihypertensive treatment. Br Med J. 1986;293:988-992.
5. Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, Wassertheil-Smoller S, Pressel S, Babcock C, Abernethy JD, Hotchkiss J, Tyler M. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA. 1985;253:657-664.
6. Marland LJ, Lutz LJ, Castle CH. Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension. 1983;5:539-544.
7. Harrap SB, Mirakian C, Datodi SR, Lever AF. Blood Pressure and lifespan following brief ACE inhibitor treatment in young spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1994;21:125-127.
8. Harrap SB, Van Der Merwe WM, Griffin SA, Macpherson F, Lever AF. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension. 1990;16:603-614.
9. Lee RM, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension. 1991;17:141-150.
10. Wu JN, Berecek KH. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor captopril. Hypertension. 1993;22:139-146.
11. Hypertension Prevention Trial Research Group. The hypertension prevention trial: three-year effects of dietary changes on blood pressure. Arch Intern Med. 1990;150:153-162.
12. Swales JD. Dietary sodium restriction in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed, vol 1. New York, NY: Raven Press; 1995:283-298.
13. Jennings G, Nelson L, Nestel P, Ester M, Korner P, Burton D, Bazelmans J. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation. 1986;73: 30-40.
14. Appel LJ, Moore TJ, Obarzanek E, Vollmer M, Svetkey L, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N, Simons-Morton D, McCullough M, Swain J, Steele P, Evans M, Miller ER, Harsha DW. A clinical trial of the effects of dietary patterns on blood pressure. The DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-1124.
15. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity. Geneva, Switzerland: World Health Organization; 1998.
16. Giudicelli JF, Freslon JL, Glasson S, Richer C. Captopril and hypertension development in the SHR. Clin Exp Hypertens. 1980;2:1083-1096.
17. Julius S, Jamerson K, Meija A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh blood pressure study. JAMA. 1990;264: 354-358.
18. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15:1-15.
19. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. Arch Intern Med. 1997;157:657-667.
20. Leitschuh M, Cupples LA, Kannel W, Gagnon D, Chobanian A. High-normal blood pressure progression to hypertension in the Framingham heart study. Hypertension. 1991;17:22-27.
21. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular diseases. N Engl J Med. 2001;345:1291-1297.
22. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
23. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26:977-980.